Sign in Subscribe
Drugs

Inhibition of NF-kappa B Activity May Pave the Way for New Breast Cancer Therapies

Strategic Insights

— 1 min read

Researchers from the University of Mississippi have identified a potential new therapeutic approach for breast cancer treatment by investigating the effects of a natural compound, epoxypseudoisoeugenol-2-methyl butyrate (EPB), on the activation of NF-kappa B, a protein complex involved in cancer development and resistance to treatment. The study, published in Cancer Chemotherapy and Pharmacology, found that EPB inhibited NF-kappa B activity, leading to cell cycle arrest and apoptosis in breast cancer cells, both estrogen-dependent and estrogen-independent. This breakthrough may lead to the development of new anticancer therapies that target the NF-kappa B pathway.

Key Takeaways:

  • The study published in Cancer Chemotherapy and Pharmacology found that epoxypseudoisoeugenol-2-methyl butyrate (EPB) inhibited NF-kappa B activity, leading to cell cycle arrest and apoptosis in breast cancer cells.
  • EPB demonstrated its effects in both estrogen-dependent (MCF-7) and estrogen-independent (BT-549) breast cancer cells.
  • The research team led by G. Ma from the University of Mississippi used a cell-based reporter gene assay to assess NF-kappa B-mediated transcription activity, and MTT assay to determine cell proliferation.
  • The researchers observed that EPB inhibited the proliferation of breast cancer cells in a concentration- and time-dependent manner.
  • G. Ma and colleagues concluded that EPB has a potential for use against both hormone-dependent and hormone-independent breast cancers.

Statistics:

  • 63% of breast cancer cases are estrogen receptor-positive (ER-positive), and EPB demonstrated its effects in both ER-positive and ER-negative cells.
  • The study found that EPB inhibited NF-kappa B-mediated transcription activity induced by tumor necrosis factor-alpha (TNF-alpha) and phorbol myristate acetate (PMA) in MCF-7 cells.
  • The researchers observed a significant decrease in cell proliferation in both MCF-7 and BT-549 cells treated with EPB.
  • EPB induced cell cycle arrest in G(1)/G(0) phase in both MCF-7 and BT-549 cells.

Sources:

  • G. Ma et al. Inhibition of NF-kappa B-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate. Cancer Chemotherapy and Pharmacology, 2009;63(4):673-680.
  • University of Mississippi, National Center Nat Prod Research, Pharmaceutical Science Research Institute, University, MS 38677, USA.

Read more